Distinction of High-Grade Neuroendocrine Carcinoma/Small Cell Carcinoma From Conventional Urothelial Carcinoma of Urinary Bladder

2011 ◽  
Vol 19 (5) ◽  
pp. 395-399 ◽  
Author(s):  
Sherry Thompson ◽  
Maureen Cioffi-Lavina ◽  
Jennifer Chapman-Fredricks ◽  
Carmen Gomez-Fernandez ◽  
Gustavo Fernandez-Castro ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Small Cell ◽  
High Grade

scholarly journals Metastatic Small Cell Carcinoma of the Urinary Bladder That Recurred in the Vagina 6 Years after Radical Cystectomy: A Case Report

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Makoto Isono ◽  
Keiichi Ito ◽  
Shinsuke Hamada ◽  
Masahiro Takahashi ◽  
Hidenori Sasa ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Radical Cystectomy ◽  
Small Cell Carcinoma ◽  
Transurethral Resection ◽  
Small Cell ◽  
Pelvic Bone ◽  
High Grade ◽  
Surgical Specimen

Small cell carcinoma (SCC) of the urinary bladder is highly aggressive and portends a poor outcome. Herein, we report a patient with recurrent SCC of the urinary bladder who experienced an unusually long-term disease-free duration after radical cystectomy. The patient was a 60-year-old woman who had undergone transurethral resection followed by radical cystectomy for muscle-invasive bladder cancer (high-grade urothelial carcinoma with adenocarcinomatous differentiation) 6 years prior; the surgical specimen had a negative surgical margin. She was referred to our hospital because of continuous bleeding from her vagina. Magnetic resonance imaging showed a mass located at the anterior wall of her residual vagina, a biopsy of which confirmed a pathological diagnosis of adenocarcinoma. The vaginal tumor and a section of the sigmoid colon were resected en bloc and were pathologically diagnosed as adenocarcinoma and SCC. We reevaluated the initial transurethral resection specimen and found SCC with foci of adenocarcinoma concomitant with high-grade urothelial carcinoma. Local recurrence and metastasis at the pelvic bone occurred 4 months later; although radiation therapy was performed, she died of the progressive disease.

scholarly journals Molecular Genetic Evidence for a Common Clonal Origin of Urinary Bladder Small Cell Carcinoma and Coexisting Urothelial Carcinoma

2005 ◽  
Vol 166 (5) ◽  
pp. 1533-1539 ◽  
Author(s):  
Liang Cheng ◽  
Timothy D. Jones ◽  
Ryan P. McCarthy ◽  
John N. Eble ◽  
Mingsheng Wang ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Molecular Genetic ◽  
Small Cell ◽  
Genetic Evidence ◽  
Clonal Origin ◽  
Molecular Genetic Evidence

Metachronous primary urothelial carcinoma following small cell carcinoma of the urinary bladder

2014 ◽  
Vol 87 (1-2) ◽  
pp. 96-98
Author(s):  
Henry H. I. Yao ◽  
Kevin Chu ◽  
Christopher Hallot ◽  
Jonathan Lewin
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell

scholarly journals Urothelial carcinoma with villoglandular differentiation (UCVGD) with small cell neuroendocrine carcinoma of urinary bladder

2019 ◽  
Vol 12 (1) ◽  
pp. bcr-2018-228017 ◽  
Author(s):  
Shilpy Jha ◽  
Suvradeep Mitra ◽  
Amit Kumar Adhya ◽  
Prasant Nayak
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Male Patient ◽  
Neuroendocrine Carcinoma ◽  
Small Cell ◽  
High Grade ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Therapeutic Implications ◽  
Muscle Invasive ◽  
Aggressive Variant

Urothelial carcinoma with villoglandular differentiation (UCVGD) is a rare aggressive variant of urothelial carcinoma. It is usually associated with high-grade urothelial carcinoma or rarely adenocarcinoma. There is only one other previous report of UCVGD associated with small cell neuroendocrine carcinoma of urinary bladder. We report the second case of UCVGD with small cell neuroendocrine carcinoma of urinary bladder in a 74-year-old non-smoker male patient. The mass was muscle invasive and also invaded the prostate. This entity needs to be confidently diagnosed due to its prognostic and therapeutic implications.

scholarly journals Review of Small Cell Carcinomas of the Prostate

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
P. Furtado ◽  
M. V. A. Lima ◽  
C. Nogueira ◽  
M. Franco ◽  
F. Tavora
Keyword(s):  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Advanced Disease ◽  
Small Cell ◽  
High Grade ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Rare Neoplasm ◽  
Carcinoma Of The Prostate

Small cell carcinoma of the prostate is a rare neoplasm, with only a few series hitherto reported. A little less than half of the cases are associated with conventional acinar adenocarcinoma, which are usually high grade. Although consensus has not been reached, the majority of patients with small cell neuroendocrine carcinoma of the prostate have advanced disease at diagnosis and disproportionally low PSA levels compared to patients with conventional acinar adenocarcinoma. Treatment consists mainly of chemotherapy associated with surgery. Radiation therapy is reserved for selected cases. This study reviews the most up-to-date information on small cell carcinomas of the prostate.

scholarly journals Long-Term Survival of a Patient with Metastatic Small-Cell Carcinoma of the Stomach Treated with Radiation Therapy

2015 ◽  
Vol 8 (3) ◽  
pp. 416-422
Author(s):  
Derek P. Bergsma ◽  
Luke O. Schoeniger ◽  
Laura Bratton ◽  
Alan W. Katz
Keyword(s):  
Radiation Therapy ◽  
Adjuvant Chemotherapy ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Small Cell ◽  
High Grade ◽  
Term Survival ◽  
Carcinoma Of The Stomach

Small-cell carcinoma (SCC), or high-grade neuroendocrine carcinoma of the stomach, is a rare subtype of extra-pulmonary SCC which is almost invariably lethal. Gastric SCC often presents with local symptoms indistinguishable from other primary stomach cancers; however, both regional and distant spread are common at the initial presentation. Depending on symptoms and patient performance status, treatment typically consists of chemotherapy or resection followed by adjuvant chemotherapy, as even patients with limited stage gastric SCC likely have micrometastatic disease at the time of diagnosis. In this case report, we describe the long-term survival of a 75-year-old male with recurrent oligometastatic high-grade neuroendocrine carcinoma of the stomach treated with radiation therapy (RT) alone. He presented with abdominal pain and dyspepsia and was found to have a 6 cm locally invasive node-positive gastric SCC initially treated with extensive surgical resection. He was not a candidate for adjuvant chemotherapy, and surveillance imaging subsequently confirmed metachronous liver and local recurrences within 1 year after surgery, which were managed with stereotactic body RT and conventional radiation, respectively. An additional para-aortic nodal recurrence was treated with intensity-modulated radiotherapy 7 years after surgery with good response. He tolerated all RT courses without notable radiation-related toxicity and remains in complete remission 11 years after initial diagnosis.

Small Cell Carcinoma of the Urinary Bladder: A Rare, Aggressive Neuroendocrine Malignancy

2012 ◽  
Vol 136 (11) ◽  
pp. 1451-1459 ◽  
Author(s):  
Xiangrong Zhao ◽  
Ethan A. Flynn
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Treatment Algorithm ◽  
Small Cell ◽  
Fatal Disease ◽  
Presenting Symptoms ◽  
Immunohistochemical Markers ◽  
Definite Treatment

Small cell carcinoma of the urinary bladder is a rare, often fatal, disease. Its presenting symptoms and gross morphology are similar to those of conventional urothelial carcinoma, whereas its prognosis is much poorer with frequent metastasis. Small cell carcinoma of the urinary bladder shares similar histology with its counterparts in other organs; however, its immunoreactivity to conventional neuroendocrine markers is low. Its diagnosis is thus considered permissible on morphologic grounds alone. Multimodal treatments are often employed, although no definite treatment algorithm has been established. For this extremely aggressive malignancy with an as-yet inconclusive etiology, further studies are needed to clarify its molecular pathogenesis to serve as a basis for diagnostic markers and therapeutic targets. The clinical, morphologic, immunoreactive, molecular, and therapeutic features of bladder small cell carcinoma are reviewed, including a detailed discussion on the utility of immunohistochemical markers.

Sign in / Sign up

Export Citation Format

Share Document